Dimension Therapeutics, Inc. , a biopharmaceutical company advancing novel, adeno-associated virus gene therapies targeting the liver, a key organ for human metabolism, today announced that it will report financial results for the full year ended December 31, 2016, on Thursday, March 9, 2017. Following distribution of the earnings release via wire services, Dimension Therapeutics will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the Company’s financial results and provide a business update.
Category: Hemophilia
uniQure Announces Presentations at Upcoming February Conferences
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 06, 2017 — uniQure N.V. , a leader in human gene therapy, today announced presentations at the following conferences taking place in February: Matthew Kapusta, chief executive officer, will participate in a Fireside Chat on Wednesday, February 15th at 3.00 p.m. EST.
Dimension Announces Interim Topline Results from Ongoing Phase 1/2…
Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B CAMBRIDGE, Mass., Jan. 31, 2017 — Dimension Therapeutics, Inc. , a biopharmaceutical company advancing novel, adeno-associated virus gene therapies targeting the liver, a key organ for human metabolism, today announced preliminary topline safety and early efficacy results of Dimension’s multi-center phase 1/2 study of DTX101 for the treatment of adult patients with moderate/severe to severe hemophilia B. DTX101, Dimension’s lead AAV candidate, is designed to deliver stable expression of blood clotting Factor IX in patients with hemophilia B, a rare genetic bleeding disorder resulting from a deficiency in FIX.
Before The Crown, there was Victoria
Julia Baird’s biography of Queen Victoria reads like a novel. It’s the story of Victoria, told, as best as possible, from her own perspective.
Cheating Death Can Cost $200,000 as Cancer Tops Pharma Sales
… revenue will propel innovation, the costs are stoking patients’ distress and creating a rift between manufacturers, health authorities and payers in many markets. Take the new lung-cancer drugs from Merck & Co., Bristol-Myers Squibb Co. and Roche …
Blood Plasma Market Is Expected to Continue Flourishing in Developed…
… to replace body fluids, clotting factors and antibodies. Plasma is used as a component for the treatment of serious health problems such as hemophilia and autoimmune disorders. Request to view Sample Report @ …
Blood Plasma Market Is Expected to Continue Flourishing in Developed…
… to replace body fluids, clotting factors and antibodies. Plasma is used as a component for the treatment of serious health problems such as hemophilia and autoimmune disorders. Request to view Sample Report @ …
Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals
Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals In 2016, these two stocks have taken paths as varied as their approaches to drug development, and the past few months have been a wild ride.
Plasma Protein Therapeutics Market – Growth to Be Facilitated by…
Plasma derived proteins are biological medicines used extensively in the treatment of rare, life-threatening, chronic, and genetic diseases. This report on the global plasma protein therapeutics market analyzes the current and future prospects of the market.
Catalyst Biosciences Completes Manufacturing Agreements for its Novel …
Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced it has secured all rights to the manufacturing process for marzeptacog alfa from Wyeth LLC, a wholly-owned subsidiary of Pfizer. Marzeptacog alfa is a next-generation Factor VIIa product that was designed to allow for the effective, long-term, subcutaneous prophylaxis in hemophilia patients with inhibitors.
SK Chemicals’ hemophilia drug approved in Canada
SK Chemicals, the biopharmaceuticals unit of South Korea’s SK Group, has obtained regulatory approval to sell its hemophilia treatment in Canada, marking another step forward in breaking into overseas markets. SK Chemicals said Sunday that Health Canada, the country’s drug regulator, has granted marketing and sales approval for Afstyla, a biologic drug for hemophilia developed by SK Chemicals and licensed out to Australian biotech firm CSL Ltd. in 2009.